A STAT Investigation By Megan Molteni and Mario Aguilar Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment
Health By Gabrielle Glaser Inequality ‘surrounds you’: A Black doctor returns to hard-hit Louisiana after treating and contracting Covid-19 in New York
Health By Amy Sokolow With science and scripture, a Baltimore pastor is fighting Covid-19 vaccine skepticism
Heavyweights By Sharon Begley ‘I really don’t know what happened to Jim’: Friends ask where James Watson’s odious attitudes about race came from
In the Lab By Andrew Joseph, Rebecca Robbins and Sharon Begley An outsider claimed to make genome-editing history — and the world snapped to attention
Exclusive By Sharon Begley Out of prison, the ‘father of gene therapy’ faces a harsh reality: a tarnished legacy and an ankle monitor
Health By Isabella Cueto ‘We don’t have a say’: Siobhan Wescott wants to elevate the voices of Native Americans in public health
Health By Usha Lee McFarling She was told ‘girls don’t do that.’ Now Margaret-Mary Wilson is a top executive at UnitedHealth Group
Heavyweights By Isabella Cueto Denizens of ‘The Cave’ became changemakers and leaders. Here are some of its notable alumni
Heavyweights By Isabella Cueto ‘Where the bats hung out’: How a basement hideaway at UC Berkeley nurtured a generation of blind innovators
Exclusive By Erin Brodwin In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’
Health By Andrew Joseph Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision
Health Tech By Casey Ross Verily’s new big hire, Amy Abernethy, on her plans to transform clinical trials — and bring in money
Heavyweights By Lev Facher Eric Lander is brilliant, connected, and controversial. Now Joe Biden wants him to ‘reinvigorate’ American science
Heavyweights By Nicholas Florko A former FDA chief, brimming with experience but lacking in niceties, surprises Washington by winning Biden’s trust
Heavyweights By Usha Lee McFarling A ‘duty to warn’: An ER doctor, shaped by war and hardship, chronicles the searing realities of Covid-19
Heavyweights By Eric Boodman As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival
In the Lab By Alex Hogan, Hyacinth Empinado and Crystal Milner Watch: How did you get your start in science? And other questions with the STAT Wunderkinds
Heavyweights By Shraddha Chakradhar At the top of her field, a Covid-19 researcher fights back against a different kind of virus: sexism and power imbalances in science
Health By Natalya Ortolano ‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community
Exclusive By Nicholas Florko and Matthew Herper Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?
Health By Andrew Joseph ‘We didn’t follow through’: He wrote the Ebola ‘lessons learned’ report for Obama. Now he weighs in on coronavirus response
Health By Andrew Joseph After 40 years, the Alzheimer’s Association sees signs of progress against a devastating disease. Is it real?
Politics By STAT Staff Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation
Health Tech By Megan Thielking A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation
Biotech By Nicholas Florko The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025
Heavyweights By Lev Facher How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda
Biotech By Nicholas Florko The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism
Politics By Nicholas Florko BIO’s new board chair on the industry’s bad reputation: ‘That’s ridiculous’
Politics By Lev Facher and Nicholas Florko Frontrunner to lead FDA, dogged by controversies, has developed knack for confronting them